drugset / Trial / NCT02055716

Sulforadex in Healthy Human Males MAD

NCT02055716

Phase 1 Completed 18 enrolled Evgen Pharma
RandomizedSingle-groupQuadruple-blindTreatment

Summary

To determine the safety and tolerability of multiple doses of Sulforadex® in healthy male volunteers over 7 days with qd or bid dosing

Timeline

Start
2014-01
Primary completion
2014-04
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Sulforaphane Small molecule 100 mg
Subject Sulforaphane Small molecule 300 mg

Indications